GlassScriptPhysician profile
Casey Lynn Ward
NPI 1427536895
$8,628.91
in general payments reported to CMS, 2019-2025
51 companies · $1,258 in 2025
The $1,258 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,071 · 2022: $2,467 · 2023: $1,157 · 2024: $2,676 · 2025: $1,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,091.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,628.63 | 2021-2025 | |
| Harmony Biosciences LLC | $696.88 | 2021-2025 | Wakix |
| Emd Serono, INC. | $583.28 | 2022-2024 | Mavenclad |
| Amneal Pharmaceuticals LLC | $353.13 | 2021-2025 | Rytary, Crexont |
| Argenx US, INC. | $324.92 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Biogen, INC. | $310.56 | 2021-2023 | Tysabri, Vumerity |
| Lundbeck LLC | $281.82 | 2023-2025 | Vyepti |
| Jazz Pharmaceuticals INC. | $256.89 | 2021-2023 | |
| Lilly USA, LLC | $248.00 | 2021-2025 | Reyvow, Emgality |
| Allergan, INC. | $195.45 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $178.39 | 2022-2023 | Trudhesa |
| Merz Pharmaceuticals, LLC | $158.87 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Amgen INC. | $148.29 | 2022-2024 | Uplizna |
| Collegium Pharmaceutical, INC. | $137.11 | 2021-2022 | |
| Ucb, INC. | $134.72 | 2021-2024 | Briviact, Rystiggo |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.